Search
Minerva Neurosciences Inc
NERVAdd to Watchlist
3.980USD
-0.040-0.99%
Close 07-31 16:00（ET）Quotes delayed by 15 min
185.42MMarket Cap
LossP/E TTM
More Details of Minerva Neurosciences Inc Company
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Minerva Neurosciences Inc Info
Ticker SymbolNERV
Company nameMinerva Neurosciences Inc
IPO dateJun 25, 2014
CEOLuthringer (Remy)
Number of employees8
Security typeOrdinary Share
Fiscal year-endJun 25
Address1601 Trapelo Road
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone16176007373
Websitehttps://www.minervaneurosciences.com/
Ticker SymbolNERV
IPO dateJun 25, 2014
CEOLuthringer (Remy)
Company Executives of Minerva Neurosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Remy Luthringer, Ph.D.
Dr. Remy Luthringer, Ph.D.
Executive Chairman of the Board of Directors, Chief Executive Officer
Executive Chairman of the Board of Directors, Chief Executive Officer
184.82K
--
Mr. Geoffrey Race
Mr. Geoffrey Race
President
President
51.32K
--
Dr. David J. Kupfer, M.D.
Dr. David J. Kupfer, M.D.
Independent Director
Independent Director
23.94K
--
Mr. Hans Peter Hasler
Mr. Hans Peter Hasler
Independent Director
Independent Director
1.25K
--
Mr. Jan G. van Heek
Mr. Jan G. van Heek
Independent Director
Independent Director
--
--
Mr. Frederick Ahlholm, CPA
Mr. Frederick Ahlholm, CPA
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
--
--
Dr. Fouzia Laghrissi-Thode, M.D.
Dr. Fouzia Laghrissi-Thode, M.D.
Independent Director
Independent Director
--
--
Dr. Inderjit Kaul, M.D.
Dr. Inderjit Kaul, M.D.
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Remy Luthringer, Ph.D.
Dr. Remy Luthringer, Ph.D.
Executive Chairman of the Board of Directors, Chief Executive Officer
Executive Chairman of the Board of Directors, Chief Executive Officer
184.82K
--
Mr. Geoffrey Race
Mr. Geoffrey Race
President
President
51.32K
--
Dr. David J. Kupfer, M.D.
Dr. David J. Kupfer, M.D.
Independent Director
Independent Director
23.94K
--
Mr. Hans Peter Hasler
Mr. Hans Peter Hasler
Independent Director
Independent Director
1.25K
--
Mr. Jan G. van Heek
Mr. Jan G. van Heek
Independent Director
Independent Director
--
--
Mr. Frederick Ahlholm, CPA
Mr. Frederick Ahlholm, CPA
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
--
--
FAQs
Who are the top five shareholders of Minerva Neurosciences Inc?
The top five shareholders of Minerva Neurosciences Inc are: Dr. Remy Luthringer, Ph.D.
How many institutions hold shares of Minerva Neurosciences Inc (NERV)?
As of 2026Q1, 64 institutions hold shares of Minerva Neurosciences Inc, with a combined market value of approximately 31.80M, accounting for 71.95% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 29614667.00.